• 한국생물공학회:학술대회논문집
• /
• 한국생물공학회 2001년도 추계학술발표대회
• /
• pp.468-470
• /
• 2001

Chitosan-alginate capsules were formed by the electrostatic interactions and had appropriate mechanical strength, permeability to albumin and stability to hepatocyte. Pig hepatocytes were isolated and immobilized in chitosan-alginate capsules. Encapsulation in 3 minutes and spheroid formation period of 24 hours were optimum condition for the high liver function. Pig hepatocytes density of $90.{\times}10^6$ cells/mL in capsules was suitable for the application to bioartificial liver support system.

• 한국연초학회지
• /
• 제4권2호
• /
• pp.37-39
• /
• 1982

This experiment was conducted to obtained basical source for gathering seeds in flue- cured (NC 2326), and to investigate some characters on the relation to gathering number of capsules per a plant; amount of gathering seeds, weight per 1000 seeds and germination rate, respectively. As a results; correlation coefficient of number of capsules and amount of gathering seeds was pros(live correlation (r =0.9771**) , Weight per 1000 seeds (0.16g) was good from 39$\pm$2 capsules and amount of gathering seeds was 4.8g. So it is considered that method of gathering seeds wise proved to be a desirable 39: 2 capsules and amount of gathering seeds was 4- 5 gram.

• 생명과학회지
• /
• 제6권1호
• /
• pp.34-39
• /
• 1996

해양 다당류인 chitosan과 alginate를 이용해서 캡슐을 제조할 수 있었으며 그 성상을 물고기 알과 같은 형태 즉 인조어란의 성상으로 만들 수 있었다. 캡슐의 크기는 공기 사출기의 유속에 의해 1~5mm로 조절할 수 있었다. 캡슐의 기계적 강도는 chitosan요액의 pH와 이온의 농도에 의해 조절할 수 있었으며 원하는 어란의 기계적 강도를 가진 인조캡슐을 제조할 수 있었다. 이러한 인조어란 대체품의 제조이외에도 타분야인 의약, 산업 및 식품 분야에 이용이 가능한 캡슐로 이용 될 것이다.

• Journal of Pharmaceutical Investigation
• /
• 제20권3호
• /
• pp.121-127
• /
• 1990

Mefenamic acid has been widely used clinically as an anti-inflammatory analgesic. It has poor solubility in water $(41\;{\mu}g/ml)$ and there is the difficulty of dissolution in the mefenamic acid capsules. A study was made to investigate the effect of various surfactants on the dissolution of mefenamic acid capsules. The surfactants used were sodium lauryl sulfate (SLS), Pluronic F-68, F-77, and F-127. Mefenamic acid capsule containing surfactant showed significantly improved dissolution characteristics. The dissolution rate was fast in the order of SLS > F-77 > F-68 > F-127 in mefenamic acid capsules containing 0.2 w/w % surfactant. SLS was selected for further study on the bioavailability in rabbits. The area under the plasma concentration-time curve $(AUC_{0-24})$ of mefenamic acid capsule containing SLS was higher than one of mefenamic acid capsule not containing surfactant.

• Korean Journal of Hydrosciences
• /
• 제5권
• /
• pp.115-124
• /
• 1994

This paper presents the results of a study conducted to improve the understanding of the characteristics of cylindrical capsule flow in a pipeline by taking into account of the effect of capsule density uniformity. The effect fo capsule density variation in the axial direction was studied both experimentally and analytically. The experiments were conducted in a 190mm diameter straight pipe 17m long. The velocity, gap and tilt of capsules were measured under various conditions. In order to interpret the data on various capsule density conditions, the stability index given in the dimensionless number was introduced. The motion of capsules in pipelines is strongly affected by the stability of the capsules characterized by the statility index. The experiments conducted proved that the stability index is a vaild criterion for explaining and correlating data on the capsule motion and the capsule denisity uniformity.

• 한국건설순환자원학회논문집
• /
• 제8권1호
• /
• pp.120-128
• /
• 2020

본 연구에서는 모르타르와 직접 혼합 가능한 결정성장형 무기재료 활용 고상 캡슐을 제조하였으며, 결정성장형 무기재료 조성비에 따라 3수준의 고상 캡슐을 제조하였다. 제조된 고상 캡슐은 시멘트 질량에 3% 혼합하여 모르타르의 품질 및 균열 치유 특성을 평가하였다. 고상 캡슐을 혼합한 모르타르의 테이블 플로우 및 공기량 평가결과 고상 캡슐의 혼합에 관계없이 테이블 플로우 및 공기량에 미치는 영향은 없는 것으로 나타났다. 고상 캡슐을 혼합한 모르타르의 water flow test 및 crack closing test에 따른 균열 치유특성 평가결과 초기 투수량이 감소하는 결과가 나타났으며, 시간 경과에 따라 반응생성물 발생하여 균열이 치유되는 것을 확인할 수 있었다.

• 한국포장학회지
• /
• 제19권2호
• /
• pp.75-80
• /
• 2013

녹두, 고구마, 물밤 전분에 propylene oxide를 0~18% 첨가하여 하이드록시프로필화 전분을 제조하여 하드캡슐 제조시 젤라틴 대체제로서의 가능성을 검토하였다. RVA 시험결과 propylene oxide 첨가량이 증가할수록 호화온도와 setback은 감소했고 최고 점도와 breakdown은 증가하였다. 팽윤력은 녹두의 경우 propylene oxide 양이 12% 이상 첨가되었을 때 급격히 증가하였고 고구마와 물밤은 9% 첨가했을때부터 증가하기 시작하였다. 투명도는 녹두가 다른 전분보다 가장 높았으며 propylene oxide 첨가량에 유의적으로 증가했고 고구마와 물밤의 경우 하이드록시프로필화 전분이 일반 전분보다는 증가했으나 propylene oxide의 양에 따른 경향성은 보이지 않았다. 붕해도 시험에서는 물밤의 경우 propylene oxide 6% 이상 첨가하였을 때 완전히 용해되었고 녹두와 고구마는 12% 이상 첨가되었을 때 완전히 용해되었다. 본 실험에서는 하이드록시프로필화 전분이 젤라틴 또는 동물성단백질을 기본으로 제조된 하드캡슐의 대체제로써 의약 산업에서 활용될 수 있는 가능성을 보여주었다. 본 연구결과를 토대로 하이드록시프로필화 전분 필름의 물성, 온도와 pH에 따른 붕해도 실험등이 추가 연구된다면 전분 하드캡슐로 상용화도 가능할 것이라 생각된다.

• Journal of Pharmaceutical Investigation
• /
• 제34권1호
• /
• pp.43-48
• /
• 2004

The purpose of the present study was to evaluate the bioequivalence of two nizatidine capsules, Axid (Lilly Korea Pharm. Co., Ltd.) and Nex (Bi-nex Pharm. Co., Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). The nizatidine release from the two nizatidine capsules in vitro was tested using KP Apparatus method with various dissolution media (pH 1.2, 4.0, 6.8 buffer solutions and water). The dissolution prefers of two nizatidine capsules were very similar at all dissolution media. Twenty four normal male volunteers were divided into two groups with a randomized 22 crossover study. After two capsules (300 mg nizatidine) were orally administrated, blood was taken and the concentrations of nizatidine in serum were determined using HPLC with UV detector. The pharmacokinetic parameters such as $AUC_t$, $C_{max}$ and $T_{max}$ were determined. The result showed that the differences in $AUC_t$, $C_{max}$ and $T_{max}$ between two nizatidine capsules based on the Axid were -6.16%, -8.26% and -1.82%, respectively. There were no sequence effects between two capsules in these parameter. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(125)(e.g., $log(0.91){\sim}log(0.97)$ and $log(0.85) {\sim}log(0.99)$ for $AUC_t$ and $C_{max}$ respectively), indicting that Nex capsule is bioequivalent to Axid capsule.

• Journal of Pharmaceutical Investigation
• /
• 제14권3호
• /
• pp.105-121
• /
• 1984

The bioavailability of rifampicin (brand A, B and C) was studied and the dissolution by foamed plastic rotating method and basket rotating method was also investigated. The results were as follows; 1. In the case of foamed plastic rotating method, it was revealed that dissolution rate of brand C was most rapid, but in the case of basket rotating method the results revealed that brand B was most rapid. Also it was observed that the dissolution rate in artificial gastric juice was more rapid than one in artificial intestinal juice, and that Avicel added in capsule increased additively the dissolution rate, particulary brand B. 2. Relative systemic availability by urine data showed that the results from all capsules filled with brand A, B and C were identical but in the case of the ripamficin capsules filled with Avicel, the results showed that Avicel increased the availability of brand A and B. 3. Area under serum concentration curve $(0{\sim}8hrs)$ was in order of $brand\;A{\fallingdotseq}brand\;C$ > brand B, but Avicel increased significantly the AUC of brand B and showed no effect in others. 4. Relative systemic availability calculated with excreted amount of rifampicin in urine was similar in each rifampicin capsules. In rifampicin (A) and rifampicin (B), Avicel which added in capsules appeared increasing tendency in urine excretion of rifampicin, but in rifampicin (C) it did not appeared. 5. Area under serum concentration curve $(0{\sim}8hrs)$ in rifampicin capsules was in order of $rifampicin(A){\fallingdotseq}rifampicin(C)$>rifampicin(B). In rifampicin (B) with Avicel capsules, area under serum concentration curve (0-8hrs.) increased significantly and in others insignificantly.

• Journal of Pharmaceutical Investigation
• /
• 제29권2호
• /
• pp.151-156
• /
• 1999

Bioequivalence of two fluoxetine capsules, the $Prozac^{\circledR}$ (Daewoong Lilly Pharmaceutical Co., Ltd.) and the $Lucetin^{\circledR}$ (Kyungdong Pharmaceutical Co., Ltd.), was evaluated according to the guideline of KFDA. Twenty normal male volunteers $(21{\sim}30\;years\;old)$ were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After three capsules containing 20 mg of fluoxetine per capsule were orally administered, blood was taken at predetermined time intervals, and the concentrations of fluoxetine in serum were determined using HPLC method with UV detector. The pharmacokinetic parameters ($AUC_t$, $C_{max}$ and $T_{max}$) were calculated and ANOVA test was utilized for the statistical analysis of parameters. The results showed that the differences in $AUC_t$, $C_{max}$ and $T_{max}$ between two capsules based on $Lucetin^{\circledR}$ capsules were -8.01 %, -7.02% and 1.49%, respectively. The powers $(1-{\beta})$ for $AUC_t$, $C_{max}$ and $T_{max}$ were 84.72%, 96.68% and 83.06%, respectively. Detectable differences $({\Delta})$ and confidence intervals were all less than ${\pm}20%$. All the parameters above met the criteria of KFDA for bioequivalence, indicating that $Lucetin^{\circledR}$ capsule is bioequivalent to $Prozac^{\circledR}$ capsule.